LYEL

$15.4343.27%4.66

Nachbörslich: 15.74+0.31 +2.01%

Lyell Immunopharma Inc (LYEL)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$10.77

Offen:

$12.09

24-Stunden-Volumen:

1,100,515

Relatives Volumen:

5.22

Marktkapitalisierung:

$378.11M

Einnahmen:

$31,000

Nettoeinkommen (Verlust:

-$246.41M

KGV:

EPS:

-$12.74

Netto-Cashflow:

-$134.42M

1W Leistung:

+41.17%

1M Leistung:

+66.63%

6M Leistung:

-25.53%

1Y Leistung:

-3.26%

1-Tages-Spanne:

$12.09$16.73

1-Wochen-Bereich:

$10.56$16.73

52-Wochen-Spanne:

$7.20$45.00

Lyell Immunopharma Inc Aktie (LYEL) Unternehmensprofil

Firmenname

Lyell Immunopharma Inc

Sektor

Healthcare

Branche

Biotechnology

Telefon

650 695-0677

Adresse

201 HASKINS WAY, SOUTH SAN FRANCISCO, USA

Mitarbeiter

161

Nächster Verdiensttermin

2026-11-11

Neueste SEC-Einreichungen

SEC

LYEL-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Lyell Immunopharma Inc Aktie (LYEL) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-08-06	Eingeleitet	Stifel	Buy
2026-07-22	Eingeleitet	B. Riley Securities	Buy
2026-05-01	Eingeleitet	Robert W. Baird	Outperform
2026-04-10	Eingeleitet	Needham	Buy
2026-03-09	Eingeleitet	Citizens	Mkt Outperform
2025-12-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-10-30	Herabstufung	BofA Securities	Buy → Underperform
2024-06-27	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-28	Herabstufung	JP Morgan	Overweight → Neutral
2022-11-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-11-11	Herabstufung	Goldman	Buy → Neutral
2022-10-17	Eingeleitet	H.C. Wainwright	Buy
2021-07-12	Eingeleitet	BofA Securities	Buy
2021-07-12	Eingeleitet	Goldman	Buy
2021-07-12	Eingeleitet	JP Morgan	Overweight
2021-07-12	Eingeleitet	Morgan Stanley	Overweight

Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	0.04	0.06	0.13	84.68	10.65
Research and development USD (M)	-	-	182.95	159.19	138.69
Operating expenses USD (M)	269.44	358.82	247.14	271.74	225.43
Operating income USD (M)	-269.40	-358.76	-247.01	-187.06	-214.78
Income before tax USD (M)	-	-	0.13	84.68	10.65
Income tax expense USD (M)	0.00	-	-	-	-
Net income USD (M)	-274.45	-342.99	-234.63	-183.12	-250.22
Basic EPS USD/shares	-16.06	-1.31	-0.93	-0.74	-1.84
Diluted EPS USD/shares	-16.06	-1.31	-0.93	-0.74	-1.84
Basic weighted shares shares (M)	17.09	261.48	250.98	247.08	0.14
Diluted weighted shares shares (M)	17.09	261.48	250.98	247.08	0.14

Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel

Aguirre Jarrad MattieuOct 12 '26
Chief Medical Officer
Transaktion
Sale
Kosten
$8.63
#Aktien
422
Wert ($)
3,642
#Aktien Gesamt
19,857
Shook DavidSep 10 '26
Chief Medical Officer
Transaktion
Sale
Kosten
$12.70
#Aktien
500
Wert ($)
6,350
#Aktien Gesamt
20,423
Hill Stephen J.Aug 21 '26
Chief Operating Officer
Transaktion
Sale
Kosten
$15.54
#Aktien
989
Wert ($)
15,369
#Aktien Gesamt
16,816
Seely LynnAug 21 '26
President and CEO
Transaktion
Sale
Kosten
$15.54
#Aktien
9,589
Wert ($)
149,013
#Aktien Gesamt
63,899
Lee Gary K.Aug 21 '26
Chief Scientific Officer
Transaktion
Sale
Kosten
$15.54
#Aktien
1,457
Wert ($)
22,642
#Aktien Gesamt
16,220
Hill Stephen J.Aug 10 '26
Chief Operating Officer
Transaktion
Sale
Kosten
$14.34
#Aktien
89
Wert ($)
1,276
#Aktien Gesamt
17,805
Seely LynnAug 10 '26
President and CEO
Transaktion
Sale
Kosten
$14.34
#Aktien
390
Wert ($)
5,593
#Aktien Gesamt
73,488
Lee Gary K.Aug 10 '26
Chief Scientific Officer
Transaktion
Sale
Kosten
$14.34
#Aktien
131
Wert ($)
1,879
#Aktien Gesamt
17,677
Bulis Veronica SanchezAug 10 '26
VP, Corporate Controller
Transaktion
Sale
Kosten
$14.34
#Aktien
621
Wert ($)
8,905
#Aktien Gesamt
14,799
Innovative Cellular TherapeutiJul 17 '26
10% Owner
Transaktion
Sale
Kosten
$13.70
#Aktien
10
Wert ($)
137
#Aktien Gesamt
2,857,480

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Aguirre Jarrad Mattieu	Chief Medical Officer	Oct 12 '26	Sale	$8.63	422	3,642	19,857
Shook David	Chief Medical Officer	Sep 10 '26	Sale	$12.70	500	6,350	20,423
Hill Stephen J.	Chief Operating Officer	Aug 21 '26	Sale	$15.54	989	15,369	16,816
Seely Lynn	President and CEO	Aug 21 '26	Sale	$15.54	9,589	149,013	63,899
Lee Gary K.	Chief Scientific Officer	Aug 21 '26	Sale	$15.54	1,457	22,642	16,220
Hill Stephen J.	Chief Operating Officer	Aug 10 '26	Sale	$14.34	89	1,276	17,805
Seely Lynn	President and CEO	Aug 10 '26	Sale	$14.34	390	5,593	73,488
Lee Gary K.	Chief Scientific Officer	Aug 10 '26	Sale	$14.34	131	1,879	17,677
Bulis Veronica Sanchez	VP, Corporate Controller	Aug 10 '26	Sale	$14.34	621	8,905	14,799
Innovative Cellular Therapeuti	10% Owner	Jul 17 '26	Sale	$13.70	10	137	2,857,480

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

Oct 29, 2026

Lyell Immunopharma stock: CMO sold 422 shares for taxes - ad-hoc-news.de

Oct 29, 2026

Oct 15, 2026

Lyell Immunopharma CMO sells 422 shares: USD 40.86 target for Lyell Immunopharma stock - ad-hoc-news.de

Oct 15, 2026

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding - Investing.com

Oct 13, 2026

Form 4 Lyell Immunopharma Inc: Jarrad Mattieu Aguirre (Chief Medical Officer) For: 12 October - Investing.com Nigeria

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com - Investing.com Nigeria

Oct 13, 2026

Form 4 Lyell Immunopharma Inc: Jarrad Mattieu Aguirre (Chief Medical Officer) For: 12 October - Investing.com Canada

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com - Investing.com UK

Oct 13, 2026

An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares. - Stock Titan

Oct 13, 2026

Sep 25, 2026

Lyell Immunopharma Inc (NASDAQ: LYEL) Share Price, LYEL Stock News, LYEL Share Price & Updates - kalkine.ca

Sep 25, 2026

Sep 21, 2026

Lyell Immunopharma (Nasdaq:LYEL) - Stock Analysis - Simply Wall Street

Sep 21, 2026

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy - Investing.com

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com India

Sep 11, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com India

Sep 11, 2026

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting By Investing.com - Investing.com Nigeria

Sep 11, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 11, 2026

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com South Africa

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares - Investing.com

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com Canada

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com UK

Sep 10, 2026

Lyell Immunopharma (LYEL) CMO discloses stock, RSUs and option awards - Stock Titan

Sep 10, 2026

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting - investing.com

Sep 10, 2026

Lyell Immunopharma advances LYL273 CAR T program - TipRanks

Sep 10, 2026

An experimental cancer treatment has moved to a manufacturing center. Lyell expects data in 2027. - Stock Titan

Sep 10, 2026

Sep 09, 2026